why choose us

First received: January 30, 2023

Clinical Trial: A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Study Status: Completed

Recruit Status: RECRUITING

Condition: Solid Tumor, Adult

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530, an Autologous Logic-gated Tmod™ Chimeric Antigen Receptor T Cell (CAR T), in Heterozygous HLA-A*02 Adult Subjects With Recurrent U

Brief Summary: The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other solid tumors that express CEA and have lost HLA-A*02 expression.The main questions this study aims to answer are:Phase 1: What is the maximum or recommended dose of A2B530 that is safe for patientsPhase 2: Does the recommended dose of A2B530 kill the solid tumor cells and protect the…

Read more